Industry: Immunotherapies to treat cancer

ViaMune is developing an immunotherapy vaccine targeting tumor-specific MUC1, a cell-surface glycoprotein that helps cancerous cells form a barrier against chemotherapeutic drugs.
ViaMune’s lead compound — MTI, still in the pre-clinical stage — promises to target aberrant MUC1 specifically and defeat tolerance to tumor antigens, aiding in tumor treatment.
The company is investigating related tumor-associated glycoproteins to expand its drug therapy pipeline.  

Company website: ViaMune

Back to companies